Literature DB >> 25039724

Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1.

Duo Huang1, Luo Anguo, Wen-Sheng Yue, Lixue Yin, Hung-Fat Tse, Chung-Wah Siu.   

Abstract

BACKGROUND: Patients with atrial fibrillation (AF) with CHA2 DS2 -VASc score of 1 (where CHA2 DS2 -VASc is CHA2 DS2 -Vascular disease, Age 65-74 years, Sex category) are recommended to receive antithrombotic therapy. Nonetheless, it remains unclear whether individual components that constitute CHA2 DS2 -VASc score contribute equally to the ischemic stroke risk, particularly in patients with CHA2 DS2 -VASc score of 1. The objective was to describe and compare the risk of ischemic stroke of the six individual components constituting CHA2 DS2 -VASc among AF patients with CHA2 DS2 -VASc score of 1. METHODS AND
RESULTS: We studied all patients with CHA2 DS2 -VASc score of 1 and no antithrombotic therapy from our cohort of 9,727 Chinese AF patients. A total of 548 patients were studied: 190 patients with CHA2 DS2 -VASc score of 0 and 358 patients with CHA2 DS2 -VASc score of 1. Of those with a baseline CHA2 DS2 -VASc score of 1, 51.1% patients aged 65-75; 29.3% patients were female; 12.0% had hypertension; 4.5% had heart failure; 2.5% had diabetes; and 0.6% had vascular disease. After 1,758 patient-years of follow-up, the annual incidence of stroke was 2.4% and 6.6% for patients with CHA2 DS2 -VASc score of 0 and 1, respectively. Compared with patients with CHA2 DS2 -VASc score of 0, patients with hypertension leading to CHA2 DS2 -VASc score of 1 were at the highest risk of stroke (Hazard ratio [HR]: 9.8, 95% confidence interval [CI]: 2.7-35.6), followed by patients aged 65-74 (HR: 3.9, 95% CI: 2.3-6.6) and female gender (HR: 2.3, 95% CI: 1.1-4.8). Heart failure, diabetes mellitus, and vascular disease were not associated with stroke.
CONCLUSION: In AF patients with CHA2 DS2 -VASc score of 1, hypertension confers the highest risk for stroke among other risk factors comprising the score. A more aggressive thromboprophylaxis strategy may be justified among AF patients with CHA2 DS2 -VASc score of 1 due to hypertension. ©2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHA2DS2-VASc score; atrial fibrillation and stroke

Mesh:

Year:  2014        PMID: 25039724     DOI: 10.1111/pace.12445

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

1.  Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

Authors:  Rochelle Sweis; José Biller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

Review 2.  Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup.

Authors:  Thomas F Deering
Journal:  J Atr Fibrillation       Date:  2017-04-30

3.  Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.

Authors:  Pak Hei Chan; Wen Hua Li; Jo Jo Hai; Hung Fat Tse; Chung Wah Siu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

4.  Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence.

Authors:  Pak Hei Chan; Jo Jo Hai; Esther W Chan; Wen Hua Li; Hung Fat Tse; Ian C K Wong; Gregory Y H Lip; Chung Wah Siu
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

5.  Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention.

Authors:  Pak-Hei Chan; Jo-Jo Hai; Duo Huang; Mei-Han Ho; Esther W Chan; Bernard Man-Yung Cheung; Annie On-On Chan; Ian Chi-Kei Wong; Hung-Fat Tse; Ivan Fan-Ngai Hung; Chung-Wah Siu
Journal:  SAGE Open Med       Date:  2016-08-04

6.  Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project.

Authors:  Qinmei Xiong; Alena Shantsila; Juxiang Li; Kui Hong; Gregory Y H Lip
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

7.  Patients with atrial fibrillation and outcomes of cerebral infarction in those with treatment of warfarin versus no warfarin with references to CHA2DS2-VASc score, age and sex - A Swedish nationwide observational study with 48 433 patients.

Authors:  Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 8.  Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.

Authors:  Tatjana S Potpara; Nikolaos Dagres; Nebojša Mujović; Dragan Vasić; Milika Ašanin; Milan Nedeljkovic; Francisco Marin; Laurent Fauchier; Carina Blomstrom-Lundqvist; Gregory Y H Lip
Journal:  Adv Ther       Date:  2016-12-08       Impact factor: 3.845

Review 9.  Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Authors:  Hans-Christoph Diener; James Aisenberg; Jack Ansell; Dan Atar; Günter Breithardt; John Eikelboom; Michael D Ezekowitz; Christopher B Granger; Jonathan L Halperin; Stefan H Hohnloser; Elaine M Hylek; Paulus Kirchhof; Deirdre A Lane; Freek W A Verheugt; Roland Veltkamp; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2017-03-21       Impact factor: 29.983

Review 10.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.